Syrris Joins Select Group of R&D 100 Award Winners
News Jul 13, 2012
As the longest established provider of laboratory scale flow chemistry systems, Syrris’ wealth of expertise in research and development - as well as its patented technologies - has propelled the modular Asia product line to the forefront of the flow chemistry market.
Designed by chemists, for chemists, Asia enables an extensive range of chemical reactions, at a wide range of temperatures and pressures, with different levels of automation to suit individual laboratory needs.
The esteemed R&D 100 Awards are a benchmark of excellence, with winners chosen by an independent panel of judges and the editors of R&D Magazine.
This award recognizes the significance of flow chemistry and, in particular, Syrris’ contribution to a technology that is enabling chemists to perform faster, safer and cleaner reactions.
Syrris’ success was achieved by establishing that the Asia flow chemistry system improves upon existing technologies, providing evidence of the system’s benefits, including its modularity and wide range of chemical compatibility, and demonstrating how this technology is proving a useful tool for chemists working in such diverse areas as academia and the pharmaceutical, petrochemical and nanoparticle industries.
Mike Hawes, CEO of Syrris, commented: “We are delighted that the Asia system has been announced as a winner of the 50th Annual R&D Awards, acknowledging the success of this groundbreaking technology, and look forward to attending the presentation ceremony in November.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE